ERBB2 and breast carcinoma: In this study, we used the HER2 over-expressing breast cancer cell line, BT474 and a lapatinib resistant derivative (BT474 LapR), in an effort to investigate the functional outcome of FOXO3 acetylation as well as the role of FOXO3 acetylation in modulating lapatinib response.